@FierceBiotech: Troubled Rigel axes 30 staffers as it maps a comeback R&D strategy. Story | Follow @FierceBiotech
@JohnCFierce: Trending on FierceBiotech: In big setback, GlaxoSmithKline's cancer immunotherapy MAGE-A3 flunks PhIII goal. Article | Follow @JohnCFierce
@RyanMFierce: In growing diabetes market, Sanofi looks beyond iPhone for mobile glucose testing. More from FierceBiotechIT | Follow @RyanMFierce
@EmilyMFierce: Matter: A Catalog for all the World's Viruses? More from the NY Times | Follow @EmilyMFierce
> Gaithersburg, MD-based GenVec ($GNVC) has reversed course on its plans to shutter the gene therapy company. The troubled biotech experienced a nasty setback when it reported that its lead therapy, TNFerade, failed a late-stage study for pancreatic cancer. But the company has since had a change of heart about its prospects for a hearing loss project partnered with Novartis ($NVS) in a $220 million deal. CEO Cynthia Collins, meanwhile, has exited the company and been replaced by CFO Douglas J. Swirsky. GenVec shares ended the day yesterday at 48 cents. Story
> Belgium's ThromboGenics has struck a deal with the U.K.'s Bicycle Therapeutics to develop and commercialize new ophthalmic drugs for a variety of conditions, including diabetic macular edema. Release
> South San Francisco-based Theravance ($THRX) reported positive topline results from a dose-ranging 7-day crossover-design Phase IIb study of its LAMA TD-4208. Release
@FierceMedDev: Siemens Dx test panel recall draws FDA's "most serious" label. Story | Follow @FierceMedDev
@MarkHFierce: FierceDiagnostics has some great new stories--check them out! FierceDiagnostics | Follow @MarkHFierce
@MichaelGFierce: Laser system gives clear, real-time image of brain tumors for surgery. Item | Follow @MichaelGFierce
> Edwards says diabetes patients may benefit from Sapien heart valve. More
> Echo Therapeutics to meet with angry shareholder. Article
> Philips joins effort to test "focused ultrasound" against metastatic bone cancer. News
Pharma News
@FiercePharma: ICYMI: Yesterday's top story: Onyx CEO will score $58M on Amgen deal. Other execs also to collect millions. More | Follow @FiercePharma
@EricPFierce: New AstraZeneca aseptic manufacturing facility at Macclesfield would add 3 dozen jobs. News | Follow @EricPFierce
@CarlyHFierce: From FierceVaccines: Will increased #flushot options confuse patients? Story | Follow @CarlyHFierce
> With $886M Astex buy, Otsuka joins Japanese rivals in overseas dealmaking. More
> Eli Lilly expects no clarity on Alimta monopoly till 2014. Story
> EU leaders slam China for targeting foreign drugmakers. Article
Pharma Manufacturing News
> PhRMA, BIO, GPhA lose suit against drug-disposal law. More
> AstraZeneca plant expansion would add 3 dozen jobs. Story
> Mylan expansions roll on. Article
> Plant in Spain gets warning letter for failing to test products. News
> Merck plant gets FDA nod for bulk varicella. Report
> Last-mile thefts grow dramatically this year. Item
Vaccines News
> PATH defends itself against Indian criticisms of HPV project. Story
> CDC reports strong uptake of Merck's Gardasil in boys. More
> Researchers promise renewed push to build on Thai HIV trial success. Article
> Doctors warn plethora of flu vaccines may confuse patients. News
> FDA clears Merck plant to produce shingles vaccine ingredient. Report
> Israel may drop planned HPV vaccination program. Item
And Finally... A new study finds that hospitals are able to command a wide range of reimbursements from insurers, depending on their market clout. Story